What to Expect From IDEXX Laboratories’ Q3 2025 Earnings Report

Core Insights - IDEXX Laboratories, Inc. is valued at a market cap of $50.7 billion and is a leader in veterinary diagnostics and software solutions [1] - The company is set to announce its fiscal Q3 earnings for 2025, with analysts projecting a profit of $3.14 per share, reflecting a 12.1% increase from the previous year [2] - Analysts expect IDEXX to report an EPS of $12.61 for the current year, which is an 18.2% increase from fiscal 2024, with further growth anticipated [3] Financial Performance - In the last fiscal quarter, IDEXX reported quarterly revenue of $1.1 billion, a 10.6% year-over-year increase, and earnings per share of $3.63, a 48.8% increase from the same quarter last year [5] - The company raised its fiscal 2025 EPS guidance to a range of $12.40–$12.76, indicating strong profitability and reinforcing investor confidence [5] Stock Performance - IDEXX shares have increased by 33.2% over the past year, outperforming the S&P 500 Index's return of 13.4% and the Health Care Select Sector SPDR Fund's decline of 8% [4] - Wall Street analysts have a "Moderate Buy" rating on IDEXX, with a mean price target of $722.36, suggesting a potential upside of 13.4% from current levels [6]